A comprehensive review of the FDA-approved labels of diabetes drugs: Indications, safety, and emerging cardiovascular safety data.

[1]  D. Matthews,et al.  Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes , 2014, Diabetes Care.

[2]  J. Silverstein,et al.  Treatment Options for Type 2 Diabetes in Youth Remain Limited. , 2016, The Journal of pediatrics.

[3]  J. Lachin,et al.  Mortality in Type 1 Diabetes in the DCCT/EDIC Versus the General Population , 2016, Diabetes Care.

[4]  P. Forsham,et al.  "Settling the UGDP controversy"? , 1975, JAMA.

[5]  T. Orchard.  The effect of rosiglitazone on overweight subjects with type 1 diabetes. , 2006, Diabetes care.

[6]  E. Bartoli,et al.  Sulfonylureas and their use in clinical practice , 2015, Archives of medical science : AMS.

[7]  D. Dunger,et al.  Expanding Treatment Options for Youth With Type 2 Diabetes: Current Problems and Proposed Solutions , 2016, Diabetes Care.

[8]  R. Beck,et al.  Effect of Metformin Added to Insulin on Glycemic Control Among Overweight/Obese Adolescents With Type 1 Diabetes: A Randomized Clinical Trial. , 2015, JAMA.

[9]  Desmond E. Williams,et al.  Changes in diabetes-related complications in the United States, 1990-2010. , 2014, The New England journal of medicine.

[10]  Deepak L. Bhatt,et al.  Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. , 2013, The New England journal of medicine.

[11]  S. Solomon,et al.  Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. , 2015, The New England journal of medicine.

[12]  D. Harlan,et al.  Effects of Exenatide Alone and in Combination With Daclizumab on β-Cell Function in Long-Standing Type 1 Diabetes , 2009, Diabetes Care.

[13]  B. Scirica.  The Safety of Dipeptidyl Peptidase 4 Inhibitors and the Risk for Heart Failure. , 2016, JAMA cardiology.

[14]  John B Buse,et al.  Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. , 2016, The New England journal of medicine.

[15]  M. Pencina,et al.  Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. , 2015, The New England journal of medicine.

[16]  R. Henry,et al.  Efficacy and Safety of Canagliflozin, a Sodium–Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes , 2015, Diabetes Care.

[17]  R. Holman,et al.  10-year follow-up of intensive glucose control in type 2 diabetes. , 2008, The New England journal of medicine.

[18]  S. Arslanian,et al.  Treatment of Type 2 Diabetes in Youth , 2011, Diabetes Care.

[19]  D. Nathan,et al.  Rationale and Design of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) , 2013, Diabetes Care.

[20]  J. Holst,et al.  Twelve-Week Treatment With Liraglutide as Add-on to Insulin in Normal-Weight Patients With Poorly Controlled Type 1 Diabetes: A Randomized, Placebo-Controlled, Double-Blind Parallel Study , 2015, Diabetes Care.

[21]  S. Inzucchi,et al.  Erratum to: Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) , 2013, Diabetologia.

[22]  W. Cushman,et al.  Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial , 2015, The Lancet.

[23]  B. Zinman,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.

[24]  S. Madsbad,et al.  Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus. , 2016, The lancet. Diabetes & endocrinology.

[25]  L. Rydén,et al.  Current perspectives on cardiovascular outcome trials in diabetes , 2016, Cardiovascular Diabetology.

[26]  D. Matthews,et al.  Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach , 2012, Diabetes Care.

[27]  Craig Wilson,et al.  Alogliptin after acute coronary syndrome in patients with type 2 diabetes. , 2013, The New England journal of medicine.

[28]  S. Saydah,et al.  Incidence Trends of Type 1 and Type 2 Diabetes among Youths, 2002–2012 , 2017, The New England journal of medicine.

[29]  David M Maahs,et al.  Current State of Type 1 Diabetes Treatment in the U.S.: Updated Data From the T1D Exchange Clinic Registry , 2015, Diabetes Care.

[30]  D. Matthews,et al.  Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach , 2012, Diabetes Care.